The agency awarded Daiichi Sankyo’s drug breakthrough, priority review and orphan drug status during its development. Pexidartinib – which will be marketed under the Turalio trade name in the ...

Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline. The European Medicines ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

today announced it entered into a Research Collaboration and Option Agreement with Daiichi Sankyo. The collaboration will leverage Nosis’ Connexa™ platform, an advanced AI-powered drug design ...